Dare Bioscience

DARE

Market cap $25.4M

Daré Bioscience, Inc. ( DARE ) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns November 17, 2025 12:00 PM EST Company Participants Jennifer Kiang Sabrina Johnson - CEO, President, Principal Financial Officer, Secretary & Director Conference Call Participants Sheryl Kingsberg Jim Simon Presentation Jennifer Kiang All right. Good morning, everyone, and thanks so much for joining us today.

Daré Bioscience, Inc. ( DARE ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Johnson - CEO, President, Principal Financial Officer, Secretary & Director Conference Call Participants Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Presentation Operator Welcome to the conference call hosted by Daré Bioscience to review the company's third quarter 2025 financial results and to provide a business update. This call is being recorded.

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.55 per share a year ago.

DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product Revenue Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued Enrollment Multiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting as well as Non-Hormonal Contraception Four Commercially Available Solutions for Women Expected Over the Next Two Years

SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2025, to review its financial results for the quarter ended September 30, 2025 and to provide a company update.

Engagement Will Expand Daré's Engagement in Advancing Women's Health Innovation and Provide Insights into One of the Most Significant Unmet Needs in Maternal Care Engagement Will Expand Daré's Engagement in Advancing Women's Health Innovation and Provide Insights into One of the Most Significant Unmet Needs in Maternal Care

Daré Bioscience, Inc. (NASDAQ:DARE ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants MarDee J. Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - CEO, President, Principal Financial Officer, Secretary & Director Operator Welcome to the conference call hosted by Daré Bioscience Therapeutics Company's Second Quarter 2025 Financial Results and to provide a business update.

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to earnings of $1.52 per share a year ago.

DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 14, 2025, to review its financial results for the quarter ended June 30, 2025 and to provide a company update.